U.S. Announces Generic Drug Tariffs, Prompting Alarm Among Indian Pharma Leaders

U.S. announces a new tariff on imported generic medicines slated for 2028, but the policy includes a two‑year delay, pushing the effective date to 2030 as part of a broader onshoring initiative aimed at boosting domestic production.

Indian Pharma CEOs warn that the tariff will lift U.S. generic drug prices, erode profit margins for Indian exporters, and could trigger a shift toward higher‑cost domestic alternatives, potentially shrinking a market worth billions of dollars for Indian manufacturers.

Senator Rubio states that the upcoming tariffs will raise serious concerns for India, calling the measure a geopolitical challenge that could strain trade ties and push Indian firms to seek alternative markets beyond the United States.

Industry Analysts note that while India’s pharmaceutical sector has built tariff‑proof strategies against Chinese competition, the new U.S. policy exposes vulnerabilities, prompting calls for diversified export destinations and stronger diplomatic engagement to safeguard growth.